이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

ClearPoint Neuro 배당금

배당금 기준 확인 0/6

ClearPoint Neuro 배당금을 지급한 기록이 없습니다.

주요 정보

n/a

배당 수익률

n/a

지급 비율

업계 평균 수익률	1.8%
다음 배당금 지급일	n/a
전 배당일	n/a
주당 배당금	n/a
주당 순이익	-US$0.75
3년 후 배당 수익률 예측	n/a

최근 배당금 업데이트

업데이트 없음

Recent updates

ClearPoint Neuro, Inc. (NASDAQ:CLPT) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

May 09

ClearPoint Neuro: Macro-Induced Multiple Compression

Apr 25

Are ClearPoint Neuro, Inc. (NASDAQ:CLPT) Investors Paying Above The Intrinsic Value?

Apr 19

Analysts Have Made A Financial Statement On ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) Yearly Report

Mar 15

Should You Investigate ClearPoint Neuro, Inc. (NASDAQ:CLPT) At US$6.18?

Jan 04

Does ClearPoint Neuro (NASDAQ:CLPT) Have A Healthy Balance Sheet?

Dec 06

Is There An Opportunity With ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) 41% Undervaluation?

Nov 06

Why We Think Shareholders May Be Considering Bumping Up ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) CEO Compensation

May 27

US$35.00 - That's What Analysts Think ClearPoint Neuro, Inc. (NASDAQ:CLPT) Is Worth After These Results

May 13

결제의 안정성과 성장

배당금 데이터 가져오기

안정적인 배당: 과거에 CLPT 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.

배당금 증가: CLPT 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.

시장 대비 배당 수익률

ClearPoint Neuro 시장 대비 배당 수익률

CLPT 배당 수익률은 시장과 어떻게 비교되나요?
세그먼트	배당 수익률
회사 (CLPT)	n/a
시장 하위 25% (US)	1.5%
시장 상위 25% (US)	4.7%
업계 평균 (Medical Equipment)	1.8%
3년 후 애널리스트 예측 (CLPT)	n/a

주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 CLPT 의 배당 수익률을 평가할 수 없습니다.

고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 CLPT 의 배당 수익률을 평가할 수 없습니다.

주주에 대한 수익 배당금

수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 CLPT 의 지급 비율을 계산하기에는 데이터가 부족합니다.

주주에 대한 현금 배당금

현금 흐름 범위: CLPT 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.

ClearPoint Neuro 배당금

배당금 기준 확인 0/6

주요 정보

최근 배당금 업데이트

Recent updates

ClearPoint Neuro, Inc. Initiates Its Full Market Release of the Smartframe

Consensus EPS estimates upgraded to US$0.66 loss

ClearPoint Neuro, Inc. (NASDAQ:CLPT) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

ClearPoint Neuro, Inc. Announces FDA Clearance of Prism Bone Anchor Accessory

ClearPoint Neuro, Inc. Announces Initiation of Limited Market Release for the SmartFrame OR™ Stereotactic System

ClearPoint Neuro: Macro-Induced Multiple Compression

ClearPoint Neuro, Inc. to Report Q1, 2024 Results on May 07, 2024

Are ClearPoint Neuro, Inc. (NASDAQ:CLPT) Investors Paying Above The Intrinsic Value?

ClearPoint Neuro, Inc., Annual General Meeting, May 15, 2024

ClearPoint Neuro, Inc. Reaffirms Revenue Guidance for the Year 2024

Analysts Have Made A Financial Statement On ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) Yearly Report

Full year 2023 earnings: EPS and revenues exceed analyst expectations

ClearPoint Neuro, Inc. Announces Preclinical Results of an in Vivo Validation Study Have Been Published in the Journal of Neurosurgery

President exercised options and sold US$69k worth of stock

New minor risk - Shareholder dilution

ClearPoint Neuro, Inc. to Report Q4, 2023 Results on Mar 12, 2024

ClearPoint Neuro, Inc. has completed a Follow-on Equity Offering in the amount of $15.000011 million.

ClearPoint Neuro, Inc. has filed a Follow-on Equity Offering.

ClearPoint Neuro, Inc. Announces FDA Clearance and First-In-Human Cases Performed with the New 2.2 Software Version and the Integrated Maestro Brain Model

Now 21% undervalued

Clearpoint Neuro Receives 510(K) Clearance for Smartframe or Stereotactic System

ClearPoint Neuro, Inc. Provides Revenue Guidance for the Full Year 2024

Should You Investigate ClearPoint Neuro, Inc. (NASDAQ:CLPT) At US$6.18?

Does ClearPoint Neuro (NASDAQ:CLPT) Have A Healthy Balance Sheet?

ClearPoint Neuro, Inc. Provides Earnings Guidance for the Year 2023

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Is There An Opportunity With ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) 41% Undervaluation?

ClearPoint Neuro, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Is ClearPoint Neuro (NASDAQ:CLPT) Using Debt In A Risky Way?

Consensus EPS estimates fall by 36%

ClearPoint Neuro, Inc. Reaffirms Its Revenue Guidance for Full Year 2023

Second quarter 2023 earnings: EPS misses analyst expectations

ClearPoint Neuro, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Consensus EPS estimates fall by 13%

ClearPoint Neuro, Inc. Reaffirms Revenue Guidance for the Year 2023

Price target increased by 19% to US$22.00

ClearPoint Neuro, Inc. (NASDAQ:CLPT) Looks Just Right With A 40% Price Jump

Full year 2022 earnings: EPS exceeds analyst expectations

ClearPoint Neuro, Inc. to Report Q4, 2022 Results on Mar 01, 2023

ClearPoint Neuro, Inc. Provides Revenue Guidance for the Year 2023

Does ClearPoint Neuro (NASDAQ:CLPT) Have A Healthy Balance Sheet?

ClearPoint Neuro, Inc. Announces First Patient Enrolled in Glioblastoma Trial Using Clearpoint Prism Neuro Laser Therapy System At Skåne University Hospital in Sweden

Price target increased to US$20.25

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

ClearPoint Neuro, Inc. Reaffirms Revenue Guidance for the Year 2022

ClearPoint Neuro, Inc. to Report Q3, 2022 Results on Nov 08, 2022

ClearPoint Neuro, Inc. Announces FDA Clearance for ClearPoint Prism™ Neuro Laser Therapy System

ClearPoint Neuro, Inc. Announces Appointment of Mazin Sabra as Chief Operating Officer

ClearPoint Neuro, Inc. Announces FDA Clearance for Software Version 2.1

ClearPoint Neuro: Continuous Great Execution

President notifies of intention to sell stock

ClearPoint Neuro: Picks & Shovels Galore

ClearPoint Neuro (NASDAQ:CLPT) Has Debt But No Earnings; Should You Worry?

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

ClearPoint Neuro, Inc. Reaffirms Revenue Guidance for the Full Year 2022

ClearPoint Neuro, Inc. to Report Q2, 2022 Results on Aug 09, 2022

ClearPoint Neuro: A 'Picks And Shovels' Biotech Company

ClearPoint Neuro, Inc. Reconstitutes its Committees

ClearPoint Neuro: Continuous Execution Despite Covid Headwind

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

ClearPoint Neuro, Inc. Revises Revenue Guidance for the Year 2022

Price target decreased to US$18.50

No longer forecast to breakeven

Is ClearPoint Neuro (NASDAQ:CLPT) Using Debt In A Risky Way?

ClearPoint Neuro, Inc., Annual General Meeting, May 24, 2022

ClearPoint Neuro: A Strong Recovery Play Once COVID Subsides

Full year 2021 earnings: EPS exceeds analyst expectations

No longer forecast to breakeven

ClearPoint Neuro, Inc. Announces Revenue Guidance for the Year of 2022

ClearPoint Neuro, Inc. Announces Resignation of Peter G. Piferi as Chief Operating Officer

ClearPoint Neuro (NASDAQ:CLPT) Has Debt But No Earnings; Should You Worry?

ClearPoint Neuro: Underlying Growth Potential Concealed By COVID

High number of new directors

Third quarter 2021 earnings released: US$0.18 loss per share (vs US$0.094 loss in 3Q 2020)